Image: (left) Dr John Brown, Chair of BioCity group and Stuart Henderson
BioCity, the Nottingham-headquartered life sciences incubation business, has appointed Stuart Henderson to the Board to help drive its growth and further strengthen its connections within the life sciences sector.
Home to more than 200 life science and healthcare companies, BioCity was founded in 2002 and now houses one of the largest networks of med-tech, bio-tech, drug discovery and healthcare companies in the UK, following the launch of MediCity Nottingham, based on the Boots campus in Beeston, along with centres at Alderley Park in Cheshire and near Glasgow.
Stuart joins BioCity at a time of growth and will use his extensive network of connections in the life sciences arena, particularly in Cambridge – one of the world’s leading concentrations of biotechnology and life sciences businesses – to facilitate and drive the creation, funding and growth of life sciences companies across the UK.
Stuart has a strong track record in the life sciences sector having previously been a partner at Deloitte and head of its European Healthcare and Life Science Practice. During this time, he worked with some of the UK’s leading biotechnology companies including Cambridge Antibody Technology, Horizon Discovery, Abcam and Acambis, guiding many through the initial public offering (IPO) process.
Stuart also sits on the Board of Oxford Biomedica plc and the Cell Therapy Catapult.
Commenting on Stuart’s appointment, Chair of BioCity Group, Dr John Brown said: “Stuart brings a wealth of life science industry experience and expertise to the BioCity board and his excellent connections in the field will enable us to find opportunities for growth.
“His knowledge of the sector will be of enormous benefit to not only BioCity but also the companies we work with and invest in.”
Stuart said: “I am delighted to be joining the BioCity board at such an exciting time. The business has experienced impressive growth in recent years and that looks set to accelerate as it continues to build its investment portfolio and expand its core incubator business.”